Detection and spread of Escherichia coli possessing the plasmid-borne carbapenemase KPC-2 in Brooklyn, New York

Clinical Infectious Diseases

Volumn 44, Issue 7, 2007, Pages 972-975

  Bratu, Simona ^a   Brooks, Steven ^b   Burney, Sibte ^b   Kochar, Sandeep ^a   Gupta, Jyoti ^c   Landman, David ^a   Quale, John ^a  

^a SUNY DOWNSTATE MEDICAL CENTER   (United States)

^b KINGSBROOK JEWISH MEDICAL CENTER   (United States)

^c Brookdale Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMPICILLIN; AZTREONAM; BACTERIAL ENZYME; CARBAPENEM; CARBAPENEMASE TYPE 2; CEFEPIME; CEFTAZIDIME; CEFTRIAXONE; COLISTIN; COTRIMOXAZOLE; ERTAPENEM; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; TOBRAMYCIN; UNCLASSIFIED DRUG;

AGED; ANALYTIC METHOD; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM DETECTION; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATE; CASE REPORT; ESCHERICHIA COLI; HOSPITAL; HUMAN; KLEBSIELLA PNEUMONIAE; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PLASMID; PRIORITY JOURNAL; UNITED STATES;

AGED; ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BETA-LACTAMASES; CARBAPENEMS; CROSS INFECTION; DISEASE OUTBREAKS; DRUG RESISTANCE, BACTERIAL; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; HUMANS; INCIDENCE; MALE; MICROBIAL SENSITIVITY TESTS; NEW YORK CITY; POLYMERASE CHAIN REACTION; POPULATION SURVEILLANCE;

EID: 33947357813     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/512370     Document Type: Article

References (29)

1. Centers for Disease Control and Prevention. National Nosocomial Infections Surveillance (NNIS) system report: data summary from January 1992 through June 2003. Am J Infect Control 2003; 31:481-98.
2. Stapleton PD, Shannon KP, French GL. Carbapenem resistance in Escherichia coli associated with plasmid-determined CMY-4 β-lactamase production and loss of an outer membrane protein. Antimicrob Agents Chemother 1999; 43:1206-10.
3. Poirel L, Heritier C, Spicq C, Nordmann P. In vivo acquisition of high-level resistance to imipenem in Escherichia coli. J Clin Microbiol 2004; 42:3831-3.
4. Miriagou V, Tzelepi E, Gianneli D, Tzouvelekis LS. Escherichia coli with a self-transferable, multiresistant plasmid coding for metallo-β-lactamase VIM-1. Antimicrob Agents Chemother 2003; 47:395-7.
5. Petrella S, Renard M, Bismuth R, Bodin L, Jarlier V, Sougakoff WP. Identification of a carbapenem-hydrolyzing class A β-lactamase, KPC-2, in two clinical strains of Enterobacter cloacae and Escherichia coli [abstract O288]. In: Program and abstracts of the 13th European Congress of Clinical Microbiology and Infectious Diseases (Glasgow). Basel, Switzerland: European Society of Clinical Microbiology and Infectious Diseases, 2003.
6. Navon-Venezia S, Chmelnitsky I, Leavitt A, Schwaber MJ, Schwartz D, Carmeli Y. Plasmid-mediated imipenem-hydrolyzing enzyme KPC-2 among multiple carbapenem-resistant Escherichia coli clones in Israel. Antimicrob Agents Chemother 2006; 50:3098-101.
7. Hong T, Moland S, Abdalhamid B, et al. Escherichia coli: development of carbapenem resistance during therapy. Clin Infect Dis 2005; 40:e84-5.
8. Quale J, Bratu S, Landman D, Heddurshetti R. Molecular epidemiology and mechanisms of carbapenem resistance in Acinetobacter baumannii endemic to New York City. Clin Infect Dis 2003; 37:214-20.
9. Sambrook J, Fritsch EF, Maniatis T. Molecular cloning: a laboratory manual. 2nd ed. Vol.1. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press, 1989.
10. Rice LB, Bonomo RA. Genetic and biochemical mechanisms of bacterial resistance to antimicrobial agents. In: Lorian V, ed. Antibiotics in laboratory medicine. 4th ed. Baltimore: Williams & Wilkins, 1996: 483-4.
11. Bradford P, Bratu S, Urban C, et al. Emergence of carbapenem-resistant Klebsiella species possessing the class A carbapenem-hydrolyzing KPC-2 and inhibitor-resistant TEM-30 β-lactamases in New York City. Clin Infect Dis 2004; 39:55-60.
12. Paterson DL, Hujer KM, Hujer AM, et al. Extended-spectrum β-lactamases in Klebsiella pneumoniae bloodstream isolates from seven countries: dominance and widespread prevalence of SHV- and CTX-M-type β-lactamases. Antimicrob Agents Chemother 2003; 47:3554-60.
13. Oliver A, Wigel LM, Rasheed KJ, McGowan JE Jr, Raney P, Tenover FC. Mechanisms of decreased susceptibility to cefpodoxime in Escherichia coli. Antimicrob Agents Chemother 2002; 46:3829-36.
14. Pratt LA, Hsing WH, Gibson KE, Silhavy TJ. From acids to OsmZ-multiple factors influence synthesis of the OmpF and OmpC porins in Escherichia coli. Mol Microbiol 1996; 20:911-7.
15. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. Supplement M100-S15. Wayne, PA: Clinical and Laboratory Standards Institute, 2005.
16. Miriagou V, Tzouvelekis LS, Rossiter S, Tzelepi E, Angulo FJ, Whichard JM. Imipenem resistance in a Salmonella clinical strain due to plasmid-mediated class A carbapenemase KPC-2. Antimicrob Agents Chemother 2003; 47:1297-300.
17. Naas T, Nordmann P, Vedel G, Poyart C. Plasmid-mediated carbapenem-hydrolyzing β-lactamase KPC in a Klebsiella pneumoniae isolate from France. Antimicrob Agents Chemother 2005; 49:4423-4.
18. Villegas MV, Lolans K, Correa A, et al. First detection of he plasmid-mediated class A carbapenemase KPC-2 in clinical isolates of Klebsiella pneumoniae from South America. Antimicrob Agents Chemother 2006; 50:2880-2.
19. Bratu S, Landman D, Haag R, et al. Rapid spread of carbapenem-resistant Klebsiella pneumoniae in New York City: a new threat to our antibiotic armamentarium. Arch Intern Med 2005; 165:1430-5.
20. Woodford N, Tierno PM Jr, Young K, et al. Outbreak of Klebsiella pneumoniae producing a new carbapenem-hydrolyzing class A β-lactamase, KPC-3, in a New York medical center. Antimicrob Agents Chemother 2004; 48:4793-9.
21. Yigit H, Queenan AM, Rasheed JK, et al. Carbapenem-resistant strain of Klebsiella oxytoca harboring carbapenem-hydrolyzing β-lactamase KPC-2. Antimicrob Agents Chemother 2003; 47:3881-9.
22. Hossain A, Ferraro MJ, Pino RM, et al. Plasmid-mediated carbapenem-hydrolyzing enzyme KPC-2 in an Enterobacter sp. Antimicrob Agents Chemother 2004; 48:4438-40.
23. Bratu S, Landman D, Alam M, Tolentino E, Quale J. Detection of KPC carbapenem-hydrolyzing enzymes in Enterobacter spp. from Brooklyn, New York. Antimicrob Agents Chemother 2005; 49:776-8.
24. Rasheed JK, Washer L, Chenoweth C, et al. The carbapenem-hydrolyzing KPC-2 enzyme produced by a clinical isolate of Citrobacter freundii [abstract C2-95]. In: Program and abstracts of the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy (Washington DC). Washington, DC: American Society for Microbiology, 2005:95.
25. Cornaglia G, Guan L, Fontana R, Satta G. Diffusion of meropenem and imipenem through the outer membrane of Escherichia coli K-12 and correlation with their antibacterial activities. Antimicrob Agents Chemother 1992; 36:1902-8.
26. Bratu S, Mooty M, Nichani S, et al. Emergence of KPC-possessing Klebsiella pneumoniae in Brooklyn, NY: epidemiology and recommendations for detection. Antimicrob Agents Chemother 2005; 49:3018-20.
27. Soothill JS, Lock PE. Screening for carbapenem-resistant bacteria. Lancet Infect Dis 2005; 5:597-9.
28. Parthasarathy P, Soothill J. A new screening method for carbapenem-resistant Acinetobacter baumannii and Pseudomonas aeruginosa. J Hosp Infect 2005; 61:357-8.
29. Iredell JR, Sintchenko V. Screening for antibiotic resistant gram-negative bacteria. Lancet Infect Dis 2006; 6:316-7.